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One of the most vital issues in stroke research is the paucity of animal studies that have
translated into treatments for human stroke patients. The August and October issues of this
journal were devoted to this topic, and raise a number of points of concern to rectify this
problem. In fact, NINDS is keenly aware, and recently hosted the workshop “Translational
Stroke research: Vision and Opportunities,” which raised similar concerns. The introductory
article encompassed this theme of transition of stroke research to develop strategies for
clinical relevance [4].

Author Manuscript

Unfortunately, there are a great number of problems and challenges to translating
experimental stroke therapies, and there is likely no one or simple solution. One major
problem is that the preclinical studies are using a homogeneous population with a similar
age and being treated at a specific timepoint. Whereas, human patients are genetically
diverse with different ages and many are consuming an assortment of pharmaceuticals.
Other confounding variables include the timing of the stroke and type of stroke. With this
diversity of the human patient, we may be overlooking potential treatments that were
effective in a specific human population but not clear because clinical studies were not
designed specifically to analyze that subgroup.
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Several papers in both issues address the shortcomings with animal models reflecting the
human condition. There is a necessity to interject co-morbidities, age and sex into existing
animal models to better mirror the heterogeneity of the human population. Most studies are
performed using young male rats. However, therapeutic testing in animal stroke models
should include assessment in subjects with co-morbidities, such as diabetes and
hypertension, which are common to most stroke patients [7]. Furthermore, there are clear
gender differences in stroke severity, and in response to treatment. These sex differences in
stroke have not been well studied at both preclinical and clinical levels [1]. One study has
shown that the administration of uric acid with tPA clearly benefits women but not men.
However, the study had to investigate the independent effect of sex to dissect out this
positive effect on women [15]. While the uric acid experience is reflective of excellent stroke
animal model to human translation, it also shows the vulnerability of translation. By not
designing the clinical trial specifically with pre-planned gender-based outcome analysis,
investigators nearly missed the potentially profound beneficial effect of uric acid on stroke
outcomes in women.
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Another vital avenue of research is the stroke immune response, which plays a critical role
in the pathophysiology of stroke, and different rodent stains have disparities in their immune
responses. These disparities affect translation between rodent species and between animal
and human, and have a critical impact on therapeutic translation of immunomodulatory
therapies [2]. With that in mind, reverse-translational methodologies, which start at
analyzing stroke in humans, may play a growing role. Should the neurointerventional suite
become one of the routine ‘laboratories’ for the stroke researcher? To achieve this, stroke
researchers must partner with their clinician colleagues to study stroke in humans, and then
bring those findings back to the lab for novel modeling.
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One potential correction for failure of translation would be approaching preclinical studies in
a similar fashion as clinical trials in design. One novel approach would be to report baseline
factors in preclinical studies that were developed for clinical trials [12]. These objective
methods would identify therapeutic approaches better suited for translation to clinical trials.
Both preclinical and clinical studies have relied on behavioral studies, but there are problems
that bias these recovery studies [11]. A possible solution is to use structural equation
modeling that benefit both preclinical and clinical studies in assessing recovery [10].
Another method is to try to model monitoring stroke animal ‘patients’ like their human
counterpart. Is there a utility to creating a rodent NIH Stroke Scale, which could be
administered quickly and repetitively to monitor pre- and post-treatment status? Data
support the role of using comorbidity analysis and improved reporting measures to further
translation of stroke therapies, as exemplified by the analysis of IL-1RA as a stroke therapy
[16].
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A multicenter phase III preclinical trial concept, such as the Multi-PART, has been discussed
as a solution to the lack of translation [6]. This approach is believed to enhance efforts to
translate preclinical studies to the clinical realm. Many in the research community support
this effort. This would change the basic research environment and culture as well as require
funding. One potential source of funding could be through industrial-academic partnerships
[5]. This partnership have proven effective in supporting randomized trials, such as MR
CLEAN, in examining intraarterial treatment for acute ischemic stroke [3].
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Stem cell therapies have shown great promise in animal models but have not been translated
to human patients. Reasons for failure could include problems with administration routes,
and lack of understanding the most efficacious components within cell therapies [17, 19].
Moreover, other potential therapeutic targets should be investigated, such as regulatory T
cells which dampen immune-based neurodegeneration [13, 18]. Improvement in current
reperfusion therapies could lead to an extended therapeutic time window allowing for more
eligible patients to be treated [8, 14]. The use of anesthestics in stroke models can affect
many physiological systems, and is a confounding factor in determining efficacy of a
treatment [9].
Stroke research is facing many impediments to attaining a treatment. A starting point would
be better integration between the basic scientist and the clinician, in which both can learn
from each other to develop better translational studies.
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